AFFIMED NV (AFMD) Stock News

USA - NASDAQ:AFMD - NL0015001ZQ0 - Common Stock

0.1815 USD

-0.1 (-34.95%)

Last: 5/19/2025, 8:00:00 PM

0.1731 USD

-0.01 (-4.63%)

After Hours: 5/19/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AFMD Latest News, Press Relases and Analysis

All

Press Releases

5 months ago - By: Zacks Investment Research - Mentions: CGEN

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: Benzinga - Mentions: PTIX HCTI ZIM FAAS ...

Dow Tumbles 200 Points; ZIM Integrated Shipping Services Posts Upbeat Earnings

5 months ago - By: Benzinga - Mentions: HCTI TSSI INZY ZENV ...

US Stocks Edge Higher; Consumer Sentiment Falls In May

5 months ago - By: Zacks Investment Research - Mentions: MRSN

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Affimed N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

5 months ago - By: Affimed N.V.

Affimed Announces Receipt of Nasdaq Delisting Notice

5 months ago - By: Zacks Investment Research - Mentions: MGTX

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: Affimed N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

5 months ago - By: Affimed N.V.

Affimed Announces Filing for the Opening of Insolvency Proceedings

5 months ago - By: Zacks Investment Research - Mentions: BTAI

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Affimed N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

6 months ago - By: Affimed N.V.

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

6 months ago - By: Affimed N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

6 months ago - By: Affimed N.V.

Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

6 months ago - By: Stocktwits

Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode

6 months ago - By: Affimed N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

6 months ago - By: Affimed N.V.

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

7 months ago - By: Affimed N.V.

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

7 months ago - By: Affimed N.V.

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

7 months ago - By: Affimed N.V.

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

7 months ago - By: Affimed N.V.

Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

10 months ago - By: Affimed N.V.

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

10 months ago - By: Affimed N.V.

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)